Zymeworks Inc
zymeworks.comWhat Do They Do?
Develops antibody-based medicines and licenses drug candidates to pharmaceutical companies for cancer, inflammation and autoimmune diseases.
10-K for FY2025, filed Mar 2, 2026Zymeworks is a global biotechnology company managing a portfolio of licensed healthcare assets and developing a diverse pipeline of novel…View ↗
We seek to leverage our expertise in protein engineering and drug chemistry to discover and develop next-generation antibody-based…View ↗
Our pipeline of multifunctional therapeutics is supported by our multispecific antibody therapeutics (“MSATs”) and antibody-drug conjugates…View ↗
Zanidatamab, our first internally developed product candidate to receive regulatory approval, illustrates the execution of this…View ↗
How Do They Make Money?
Partners pay upfront for licenses and platform access, for research as Zymeworks performs it, and when development or approval milestones are reached; Zymeworks also receives royalties tied to partner product sales.
10-K for FY2025, filed Mar 2, 2026The Company has entered into a number of collaboration and licensing agreements. Promised deliverables within these agreements may include…View ↗
non-refundable, upfront license and platform technology access fees; research, development and regulatory milestone payments; research…View ↗
At the inception of each arrangement that includes research, development or regulatory milestone payments, the Company evaluates whether…View ↗
Payments by the licensees in exchange for research and development activities performed by the Company on behalf of the licensee are…View ↗
In addition, we could be eligible to receive future commercial milestones and increased royalties as additional indications of Ziihera are…View ↗
$106M
-
10-K for FY2025, filed Mar 2, 2026
$106M ↗
Who Are Their Customers?
Pharmaceutical companies, including Jazz, BeOne and Johnson & Johnson, partner with Zymeworks on drug development. Jazz and BeOne hold rights to commercialize zanidatamab in their territories, while Zymeworks plans to use partners for commercial capabilities rather than market its own candidates.
10-K for FY2025, filed Mar 2, 2026Zanidatamab, our first internally developed product candidate to receive regulatory approval, illustrates the execution of this…View ↗
Pasritamig is a first-in-class, bispecific T cell engager (“TCE”) targeting human kallikrein 2 (“KLK2”), and was engineered using…View ↗
As a clinical-stage biopharmaceutical company, we do not currently possess the commercial infrastructure required to launch and market our…View ↗
To access the sales, marketing and distribution capacity required to market our drug candidates, we plan to selectively establish…View ↗
Do Revenues Turn Into Profits?
No. It lost $81.1M in FY2025.
10-K for FY2025, filed Mar 2, 2026
−$92.5MView ↗
10-K for FY2025, filed Mar 2, 2026
−$81.1MView ↗
10-K for FY2025, filed Mar 2, 2026
−$34.5MView ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 6, 2026
−$45MView ↗
- ▼ Now a loss
- vs $2.3M in Q2 FY2025
-
Aug 25, 2026
Jazz received U.S. approval for Ziihera regimens in first-line GEA
The approvals triggered a $250 million milestone payment to Zymeworks.
Sources
8-K, filed Aug 25, 2026
Pursuant to the terms of the License and Collaboration Agreement, Zymeworks has earned a milestone payment of $250 million based on the FDA…View ↗
-
Jun 29, 2026
Agreed to acquire Theravance Biopharma
The proposed deal would add YUPELRI, a COPD medicine, and related cash flows.
Sources
8-K, filed Jun 29, 2026
Vancouver, British Columbia (June 29, 2026) – Zymeworks Inc. (Nasdaq: ZYME) (the “Company”), a biotechnology company managing a portfolio…View ↗
-
Apr 1, 2026
Appointed Kristin Stafford as chief financial officer
Sources
8-K, filed Apr 1, 2026
On March 31, 2026, Zymeworks Inc. (the “Company”) appointed Ms. Kristin Stafford, age 44, as Executive Vice President, Chief Financial…View ↗
Growing. Revenue grew 4.0x in 4 years, from $26.7M in FY2021 to $106M in FY2025, about 41% a year.
From drug development to asset aggregation
The older report emphasizes discovering, developing and commercializing biotherapeutics through an integrated drug-development platform. The latest report frames the business around managing licensed assets and growing royalty and milestone cash flows, alongside selective acquisitions and internal research.
10-K for FY2022, filed Mar 7, 2023 10-K for FY2025, filed Mar 2, 2026Zymeworks is a global biotechnology company managing a portfolio of licensed healthcare assets and developing a diverse pipeline of novel…View ↗
Our strategy is focused on compounding long-term stockholder value through a combination of royalty growth, strategic acquisitions, and…View ↗
Through our asset and royalty aggregation strategy, we seek to optimize future cash flows from a growing portfolio of licensed products and…View ↗
Strategic AcquisitionsView ↗
Who Do They Compete With?
Competes with F. Hoffmann-La Roche, Novartis Pharmaceuticals, Puma Biotechnology, AstraZeneca, Daiichi Sankyo, Seagen, MacroGenics, Jiangsu HengRui Medicine, Pfizer, Alphamab, BioNTech, Boehringer, Bayer, AbbVie, Genmab, Eli Lilly, Lepu/Miracogen, BioCity, Legend Biotech, and Amgen
10-K for FY2025, filed Mar 2, 2026Zanidatamab is being developed for patients with solid tumors that express HER2, including patients with tumors expressing low levels of…View ↗
Loading...
